Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 156 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:

Last Modified: 7/6/2007


1.		Phase II-III FAM (5-FU/ADR/MITO) vs V-FAM (FAM/VCR) vs Phase II Agent Chemotherapy for Advanced Gastric Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-7841

Last Modified: 6/1/1997


2.		Phase II-III Chemotherapy with CAP (CTX/ADR/CACP) vs AMSA for Advanced Transitional Cell Cancer of the Urinary Bladder (Summary Last Modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-7922


3.		Phase II/III Combination Chemotherapy with AMSA/AZC or AMSA/VP-16 for Acute Nonlymphocytic Leukemia Refractory to Standard Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								NCI-D82-013-686


4.		Phase II/III Consolidation Chemotherapy with VP-16/AMSA/AZC Following Induction with DNM/ARA-C/TG for Adult Primary or Secondary Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								NCI-D82-051-605


5.		Phase II/III Study of Induction with ARA-C/ADR plus Intensive Consolidation with Various Combinations of ADR, ARA-C, and AMSA for AML

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				physiologic 70 and under				NCI				RPMI-PPC-744 NCI-T83-0960D


6.		Phase II-III Chemotherapy with MeGAG or CLZ or AMSA or CTX/VCR/MTX for Colorectal Adenocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified				NCI				EST-1277R

Last Modified: 5/23/2007


7.		Phase II-III Trial of Neocarzinostatin vs m-AMSA or ADR in Advanced Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				EST-1280

Last Modified: 4/20/2006


8.		Phase II/III Pilot Study of Induction and Intensification Chemotherapy with VP-16, ARA-C, DNR, 5-AZ, and m-AMSA, Using "Modelled" Plasma Drug Concentrations of VP-16 and ARA-C, in Children with Acute Nonlymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21				NCI				SJCRH-AML-87 NCI-T86-0203D, T86-0203


9.		Phase II/III Combination Chemotherapy with AMSA/ARA-C for Reinduction and AMSA/VP-16 for Maintenance in Children with Relapsed ANLL

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				under 22				NCI				CCG-201

Last Modified: 10/1/1991


10.		Phase II/III Randomized Comparison of VP-16/AMSA vs VP-16/AMSA/AZC in Children with Refractory ANLL (Summary Last Modified 10/91)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				21 and under				NCI				POG-8820

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute